DELRAY BEACH, Fla., March 21, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB:EXDI; OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products, announced it has appointed Emiliano Aloi as President.
Philip J. Young, CEO of Exactus, stated: “We are excited to welcome Mr. Aloi as our President. His extensive experience in agroindustrial supply chain development as well as in all aspects of the hemp value chain will be critical as he directs the 2019 grow and processing at our recently acquired 200-acre industrial hemp farm, Exactus One World. A third-generation family farmer, Mr. Aloi is a pioneer in the space, and has been involved successfully in dozens of agroindustrial projects around the world over his career. We are proud of the team we are building and look forward to completing our mission of becoming the leading company in the industrial hemp derived CBD industry. A primary example of our leadership is the combined vision to allow all end users 100% traceability of all of our products.”
Prior to being appointed President, Mr. Aloi has served as a member of the Exactus Advisory Board. Before joining Exactus Inc., Mr. Aloi started working in the hemp industry in 2014 in Uruguay, where he achieved the first country-wide agricultural permit for flower cultivation in 2016. In 2018, he co-founded Ceed2Med, LLC, a global sourcing and distribution platform for industrial hemp and industrial hemp-derived products. From January 2017, to November 2017, Mr. Aloi served as Vice President and Director of Strategic Development for GenCanna Global, Inc., where he initiated a go-to-market strategy, recruited the commercial leadership team, developed compliance, executed product launches, and began entry into European markets.
Emiliano Aloi, President of Exactus commented: “I have been impressed working side-by-side with the Exactus team and am thrilled to be joining as President. Our vision of the business is aligned and I am proud to leverage my skills to grow our rapidly evolving platform.”
In addition, Mr. Aloi co-sponsored research programs for Stevia and Aloe Vera extraction methods from 2010 to 2012 and participated in the insertion of Chia as a novel crop in Paraguay in 2011. Mr. Aloi also co-developed the agricultural solid biofuels program for Loma Negra, a Camargo Correas Cement company subsidiary from 2009 to 2011.
In the three months since entering the hemp derived CBD marketplace, Exactus has succeeded in partnering with experienced producers, executed a supply and development agreement with Ceed2Med, acquired a majority stake in a highly desirable farm property, completed its first commercial sale of 750mg full spectrum advanced absorption tinctures, and recapitalized with a greatly simplified capital structure.
For information about Exactus, their products, and availability, please call 804-205-5036 or email, ir@exactusinc.com.
About Exactus:
Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. That amount has not been shown to make a person feel "high." THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics. For more information about Exactus: www.exactusinc.com.
Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2017 filed with the Securities and Exchange Commission (the "SEC") on April 2, 2018 and under the heading “Risk Factors” in our Current Report on Form 8-K filed with the SEC on January 14, 2019, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.
Safe Harbor - Forward Looking Statements
The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.
For more information:
Company Contact:
Andrew Johnson
509.999.9696
ir@exactusinc.com